Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Complexity, cost, and content - three important factors for translation of clinical protein mass spectrometry tests, and the case for apolipoprotein C-III proteoform testing.

Nedelkov D, Hu Y.

Clin Chem Lab Med. 2019 Dec 13. pii: /j/cclm.ahead-of-print/cclm-2019-0977/cclm-2019-0977.xml. doi: 10.1515/cclm-2019-0977. [Epub ahead of print]

PMID:
31834860
2.

ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors.

Kegulian NC, Ramms B, Horton S, Trenchevska O, Nedelkov D, Graham MJ, Lee RG, Esko JD, Yassine HN, Gordts PLSM.

Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2145-2156. doi: 10.1161/ATVBAHA.119.312723. Epub 2019 Aug 8.

PMID:
31390883
3.

Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes.

Nedelkov D.

Proteomes. 2017 Oct 15;5(4). pii: E27. doi: 10.3390/proteomes5040027. Review.

4.

Top-down mass spectrometric immunoassay for human insulin and its therapeutic analogs.

Nedelkov D, Niederkofler EE, Oran PE, Peterman S, Nelson RW.

J Proteomics. 2018 Mar 20;175:27-33. doi: 10.1016/j.jprot.2017.08.001. Epub 2017 Aug 3. Review.

PMID:
28780057
5.

Human proteoforms as new targets for clinical mass spectrometry protein tests.

Nedelkov D.

Expert Rev Proteomics. 2017 Aug;14(8):691-699. doi: 10.1080/14789450.2017.1362337. Review.

PMID:
28756725
6.

Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions.

Mendoza S, Trenchevska O, King SM, Nelson RW, Nedelkov D, Krauss RM, Yassine HN.

J Clin Lipidol. 2017 Jan - Feb;11(1):224-233.e2. doi: 10.1016/j.jacl.2016.12.009. Epub 2016 Dec 28.

7.

Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring.

Liu C, Zhao Z, Fan J, Lyon CJ, Wu HJ, Nedelkov D, Zelazny AM, Olivier KN, Cazares LH, Holland SM, Graviss EA, Hu Y.

Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3969-3974. doi: 10.1073/pnas.1621360114. Epub 2017 Mar 27.

8.

Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.

Trenchevska O, Nelson RW, Nedelkov D.

Proteomes. 2016 Mar 17;4(1). pii: E13. doi: 10.3390/proteomes4010013. Review.

9.

PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction.

Guzman-Villanueva D, Migrino RQ, Truran S, Karamanova N, Franco DA, Burciu C, Senapati S, Nedelkov D, Hari P, Weissig V.

J Liposome Res. 2018 Jun;28(2):97-105. doi: 10.1080/08982104.2016.1274756. Epub 2017 Feb 10.

10.

Mass spectrometry protein tests: ready for prime time (or not).

Nedelkov D.

Expert Rev Proteomics. 2017 Jan;14(1):1-7. doi: 10.1080/14789450.2017.1256777. Epub 2016 Nov 13. Review.

PMID:
27807991
11.

Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes.

Azizkhanian I, Trenchevska O, Bashawri Y, Hu J, Koska J, Reaven PD, Nelson RW, Nedelkov D, Yassine HN.

J Clin Lipidol. 2016 Jul-Aug;10(4):808-815. doi: 10.1016/j.jacl.2016.03.001. Epub 2016 Mar 8.

12.

Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms.

Trenchevska O, Nelson RW, Nedelkov D.

Bioanalysis. 2016 Aug;8(15):1623-1633. Epub 2016 Jul 11. Review.

13.

Development of quantitative mass spectrometric immunoassay for serum amyloid A.

Trenchevska O, Yassine HN, Borges CR, Nelson RW, Nedelkov D.

Biomarkers. 2016 Dec;21(8):743-751. doi: 10.1080/1354750X.2016.1201533. Epub 2016 Jul 22.

14.

The association of plasma cystatin C proteoforms with diabetic chronic kidney disease.

Yassine HN, Trenchevska O, Dong Z, Bashawri Y, Koska J, Reaven PD, Nelson RW, Nedelkov D.

Proteome Sci. 2016 Mar 25;14:7. doi: 10.1186/s12953-016-0096-7. eCollection 2016.

15.

Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.

Koska J, Yassine H, Trenchevska O, Sinari S, Schwenke DC, Yen FT, Billheimer D, Nelson RW, Nedelkov D, Reaven PD.

J Lipid Res. 2016 May;57(5):894-905. doi: 10.1194/jlr.P064816. Epub 2016 Mar 3.

16.

The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides.

Yassine HN, Trenchevska O, Ramrakhiani A, Parekh A, Koska J, Walker RW, Billheimer D, Reaven PD, Yen FT, Nelson RW, Goran MI, Nedelkov D.

PLoS One. 2015 Dec 3;10(12):e0144138. doi: 10.1371/journal.pone.0144138. eCollection 2015.

17.

Applications of MALDI Mass Spectrometry in Clinical Chemistry.

Duncan MW, Nedelkov D, Walsh R, Hattan SJ.

Clin Chem. 2016 Jan;62(1):134-43. doi: 10.1373/clinchem.2015.239491. Epub 2015 Nov 19. Review.

18.

Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms.

Trenchevska O, Schaab MR, Nelson RW, Nedelkov D.

Methods. 2015 Jun 15;81:86-92. doi: 10.1016/j.ymeth.2015.02.020. Epub 2015 Mar 7.

19.

The Application of Multiple Reaction Monitoring to Assess Apo A-I Methionine Oxidations in Diabetes and Cardiovascular Disease.

Yassine HN, Jackson AM, Reaven PD, Nedelkov D, Nelson RW, Lau SS, Borchers CH.

Transl Proteom. 2014 Dec 1;4-5:18-24.

20.

Serum amyloid a truncations in type 2 diabetes mellitus.

Yassine HN, Trenchevska O, He H, Borges CR, Nedelkov D, Mack W, Kono N, Koska J, Reaven PD, Nelson RW.

PLoS One. 2015 Jan 21;10(1):e0115320. doi: 10.1371/journal.pone.0115320. eCollection 2015.

21.

Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants.

Trenchevska O, Sherma ND, Oran PE, Reaven PD, Nelson RW, Nedelkov D.

J Proteomics. 2015 Feb 26;116:15-23. doi: 10.1016/j.jprot.2014.12.011. Epub 2014 Dec 27.

22.

Mass Spectrometric Immunoassay for the qualitative and quantitative analysis of the cytokine Macrophage Migration Inhibitory Factor (MIF).

Sherma ND, Borges CR, Trenchevska O, Jarvis JW, Rehder DS, Oran PE, Nelson RW, Nedelkov D.

Proteome Sci. 2014 Oct 14;12(1):52. doi: 10.1186/s12953-014-0052-3. eCollection 2014.

23.

Delineation of concentration ranges and longitudinal changes of human plasma protein variants.

Trenchevska O, Phillips DA, Nelson RW, Nedelkov D.

PLoS One. 2014 Jun 23;9(6):e100713. doi: 10.1371/journal.pone.0100713. eCollection 2014.

24.

An automated, high-throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA-HR/AM).

Peterman S, Niederkofler EE, Phillips DA, Krastins B, Kiernan UA, Tubbs KA, Nedelkov D, Prakash A, Vogelsang MS, Schoeder T, Couchman L, Taylor DR, Moniz CF, Vadali G, Byram G, Lopez MF.

Proteomics. 2014 Jun;14(12):1445-56. doi: 10.1002/pmic.201300300. Epub 2014 May 14.

PMID:
24668948
25.

Parallel workflow for high-throughput (>1,000 samples/day) quantitative analysis of human insulin-like growth factor 1 using mass spectrometric immunoassay.

Oran PE, Trenchevska O, Nedelkov D, Borges CR, Schaab MR, Rehder DS, Jarvis JW, Sherma ND, Shen L, Krastins B, Schwenke DC, Reaven PD, Nelson RW.

PLoS One. 2014 Mar 24;9(3):e92801. doi: 10.1371/journal.pone.0092801. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e95812. Lopez, Mary F [removed].

26.

Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1.

Niederkofler EE, Phillips DA, Krastins B, Kulasingam V, Kiernan UA, Tubbs KA, Peterman SM, Prakash A, Diamandis EP, Lopez MF, Nedelkov D.

PLoS One. 2013 Nov 21;8(11):e81125. doi: 10.1371/journal.pone.0081125. eCollection 2013.

27.

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.

Krastins B, Prakash A, Sarracino DA, Nedelkov D, Niederkofler EE, Kiernan UA, Nelson R, Vogelsang MS, Vadali G, Garces A, Sutton JN, Peterman S, Byram G, Darbouret B, PĂ©russe JR, Seidah NG, Coulombe B, Gobom J, Portelius E, Pannee J, Blennow K, Kulasingam V, Couchman L, Moniz C, Lopez MF.

Clin Biochem. 2013 Apr;46(6):399-410. doi: 10.1016/j.clinbiochem.2012.12.019. Epub 2013 Jan 8.

28.

Mass spectrometry-based protein assays for in vitro diagnostic testing.

Nedelkov D.

Expert Rev Mol Diagn. 2012 Apr;12(3):235-9. doi: 10.1586/erm.12.15. Review.

PMID:
22468814
29.

Mass spectrometric immunoassay for quantitative determination of transthyretin and its variants.

Trenchevska O, Kamcheva E, Nedelkov D.

Proteomics. 2011 Sep;11(18):3633-41. doi: 10.1002/pmic.201100023. Epub 2011 Aug 9.

30.

Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants.

Kiernan UA, Phillips DA, Trenchevska O, Nedelkov D.

PLoS One. 2011 Mar 30;6(3):e17282. doi: 10.1371/journal.pone.0017282.

31.

Targeted quantitative mass spectrometric immunoassay for human protein variants.

Trenchevska O, Nedelkov D.

Proteome Sci. 2011 Apr 8;9(1):19. doi: 10.1186/1477-5956-9-19.

32.

Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms.

Trenchevska O, Kamcheva E, Nedelkov D.

J Proteome Res. 2010 Nov 5;9(11):5969-73. doi: 10.1021/pr1007587. Epub 2010 Sep 23.

33.

Integration of SPR biosensors with mass spectrometry (SPR-MS).

Nedelkov D.

Methods Mol Biol. 2010;627:261-8. doi: 10.1007/978-1-60761-670-2_18.

PMID:
20217628
34.

Volumetric mass spectrometry protein arrays.

Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW.

Methods Mol Biol. 2007;382:333-43. doi: 10.1007/978-1-59745-304-2_21.

PMID:
18220241
35.

Population proteomics: investigation of protein diversity in human populations.

Nedelkov D.

Proteomics. 2008 Feb;8(4):779-86. doi: 10.1002/pmic.200700501. Review.

PMID:
18210367
36.

Development of surface plasmon resonance mass spectrometry array platform.

Nedelkov D.

Anal Chem. 2007 Aug 1;79(15):5987-90. Epub 2007 Jun 23.

37.

Investigation of human protein variants and their frequency in the general population.

Nedelkov D, Phillips DA, Tubbs KA, Nelson RW.

Mol Cell Proteomics. 2007 Jul;6(7):1183-7. Epub 2007 Apr 27.

38.

Mass spectrometry-based immunoassays for the next phase of clinical applications.

Nedelkov D.

Expert Rev Proteomics. 2006 Dec;3(6):631-40. Review.

PMID:
17181477
39.
40.
41.

Surface plasmon resonance-enabled mass spectrometry arrays.

Nedelkov D, Tubbs KA, Nelson RW.

Electrophoresis. 2006 Sep;27(18):3671-5.

PMID:
16915566
42.

Quantitative multiplexed C-reactive protein mass spectrometric immunoassay.

Kiernan UA, Addobbati R, Nedelkov D, Nelson RW.

J Proteome Res. 2006 Jul;5(7):1682-7.

PMID:
16823976
43.

High-throughput affinity mass spectrometry.

Kiernan UA, Nedelkov D, Niederkofler EE, Tubbs KA, Nelson RW.

Methods Mol Biol. 2006;328:141-50.

PMID:
16785646
44.

Surface plasmon resonance mass spectrometry for protein analysis.

Nedelkov D, Nelson RW.

Methods Mol Biol. 2006;328:131-9.

PMID:
16785645
45.

Population proteomics: the concept, attributes, and potential for cancer biomarker research.

Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW.

Mol Cell Proteomics. 2006 Oct;5(10):1811-8. Epub 2006 May 30. Review.

46.

Development of recombinant-based mass spectrometric immunoassay with application to resistin expression profiling.

Tubbs KA, Kiernan UA, Niederkofler EE, Nedelkov D, Bieber AL, Nelson RW.

Anal Chem. 2006 May 15;78(10):3271-6.

PMID:
16689526
47.

High-throughput MS-based protein phenotyping: application to haptoglobin.

Tubbs KA, Kiernan UA, Niederkofler EE, Nedelkov D, Bieber AL, Nelson RW.

Proteomics. 2005 Dec;5(18):5002-7.

PMID:
16281186
48.

Investigating diversity in human plasma proteins.

Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10852-7. Epub 2005 Jul 25.

49.

Population proteomics: addressing protein diversity in humans.

Nedelkov D.

Expert Rev Proteomics. 2005 Jun;2(3):315-24.

PMID:
16000079
50.

Quantitative mass spectrometric immunoassay of insulin like growth factor 1.

Nelson RW, Nedelkov D, Tubbs KA, Kiernan UA.

J Proteome Res. 2004 Jul-Aug;3(4):851-5.

PMID:
15359740

Supplemental Content

Loading ...
Support Center